EL:EURONEXT PARISEssilorLuxottica SA Analysis
Data as of 2026-03-10 - not real-time
$92.63
Latest Price
8/10Risk
Risk Level: High
Executive Summary
The stock is trading at $92.63, well below its 20‑day SMA of 105.60 and 50‑day SMA of 109.43, suggesting a short‑term downtrend despite a RSI of 30.1 that signals oversold conditions. Technical momentum is bearish, with the MACD line at -3.95 sitting under its signal line of -1.93, and the price is approaching the identified support level of 88.17. Recent earnings surprised to the upside, reporting EPS of $0.89 versus expectations of $0.84 and prompting management to raise full‑year guidance, which provides a positive catalyst. However, the company’s fundamentals remain strained: a negative profit margin of -1.2%, a ROE of -4.3%, and a debt‑to‑equity ratio near 233% raise concerns about profitability and balance‑sheet resilience. The DCF fair‑value estimate of $65.02 is far below the current market price, indicating the stock is overvalued relative to intrinsic calculations. Valuation metrics such as a forward P/E of 30.6 and a price‑to‑book of 8.31 reinforce this premium pricing. Dividend yield sits at a modest 1.5% but the payout ratio exceeds 470%, making the dividend unlikely to be sustainable. Volatility is high at roughly 74% over the past 30 days and beta exceeds 1.5, pointing to amplified price swings. Analyst sentiment remains cautiously optimistic with a consensus “Buy” rating, yet HSBC downgraded the stock to “Hold,” reflecting divergent views. In this context, the stock presents a mixed picture: technical oversold signals and earnings momentum counterbalanced by weak profitability, elevated leverage, and an inflated market price.
Market Outlook
Short Term
< 1 yearPositive
Model confidence: 6/10
Key Factors
- Earnings beat and raised guidance
- Oversold RSI indicating potential bounce
- Proximity to support level at $88.17
Medium Term
1–3 yearsNeutral
Model confidence: 5/10
Key Factors
- High valuation relative to DCF
- Elevated debt‑to‑equity ratio
- Persistent negative profit margin
Long Term
> 3 yearsCautious
Model confidence: 7/10
Key Factors
- Sustained overvaluation and weak fundamentals
- Unsustainable dividend payout
- High volatility and beta increasing risk exposure
Key Metrics & Analysis
Financial Health
Revenue Growth5.60%
Profit Margin-1.21%
P/E Ratio30.6
ROE-4.34%
ROA4.42%
Debt/Equity232.94
P/B Ratio8.3
Op. Cash Flow$1.7B
Free Cash Flow$1.7B
Technical Analysis
TrendNeutral
RSI30.1
Support$88.17
Resistance$117.57
MA 20$105.60
MA 50$109.43
MA 200$93.84
MACDBearish
VolumeStable
Fear & Greed Index75.89
Valuation
Fair Value$65.02
Target Price$109.70
Upside/Downside18.42%
GradeOvervalued
TypeBlend
Dividend Yield1.51%
Risk Assessment
Beta1.54
Volatility73.97%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.